BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 16636798)

  • 21. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
    Lehne G; Mørkrid L; den Boer M; Rugstad HE
    Int J Clin Pharmacol Ther; 2000 Apr; 38(4):187-95. PubMed ID: 10783828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
    Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
    Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
    Diah SK; Smitherman PK; Aldridge J; Volk EL; Schneider E; Townsend AJ; Morrow CS
    Cancer Res; 2001 Jul; 61(14):5461-7. PubMed ID: 11454692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
    Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
    Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sterically stabilized polymeric nanoparticles with a combinatorial approach for multi drug resistant cancer: in vitro and in vivo investigations.
    Zafar S; Negi LM; Verma AK; Kumar V; Tyagi A; Singh P; Iqbal Z; Talegaonkar S
    Int J Pharm; 2014 Dec; 477(1-2):454-68. PubMed ID: 25445525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.
    Gujarati NA; Zeng L; Gupta P; Chen ZS; Korlipara VL
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4698-4704. PubMed ID: 28916341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
    Benderra Z; Faussat AM; Sayada L; Perrot JY; Chaoui D; Marie JP; Legrand O
    Clin Cancer Res; 2004 Dec; 10(23):7896-902. PubMed ID: 15585622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
    D'Cunha R; Bae S; Murry DJ; An G
    Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
    Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
    Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.
    Ling G; Zhang T; Zhang P; Sun J; He Z
    Int J Nanomedicine; 2016; 11():4077-91. PubMed ID: 27601896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
    Kowalski P; Stein U; Scheffer GL; Lage H
    Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.
    Moretti JL; Duran Cordobes M; Starzec A; de Beco V; Vergote J; Benazzouz F; Boissier B; Cohen H; Safi N; Piperno-Neumann S; Kouyoumdjian JC
    J Nucl Med; 1998 Jul; 39(7):1214-8. PubMed ID: 9669397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells.
    Ma Y; Wink M
    Phytother Res; 2010 Jan; 24(1):146-9. PubMed ID: 19548284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
    Song JG; Lee YS; Park JA; Lee EH; Lim SJ; Yang SJ; Zhao M; Lee K; Han HK
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):735-44. PubMed ID: 27520631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
    Zahra R; Furqan M; Ullah R; Mithani A; Saleem RSZ; Faisal A
    PLoS One; 2020; 15(6):e0233993. PubMed ID: 32484843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.